Skip to content
Home
Guidelines
Appropriate Use Criteria
Technology Overviews
About Us
Contact
Implementation Resources
Resources
Search for:
Home
Guidelines
Appropriate Use Criteria
Technology Overviews
About Us
Contact
Implementation Resources
Resources
Home
References
(49) Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 1997;7(5):488-495.
PubMed ID:
9425508
Go to Top